JK
Insider
Justin B. Klee
Co-Chief Executive OfficerJustin B. Klee (Co-Chief Executive Officer) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Amylyx Pharmaceuticals, Inc. (AMLX). The largest single filing was $1.8M of AMLX (136,193 sh × $13.58, as filed), executed Jan 15.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.9M
shares × price, as filed
Last traded
Sep 10
Filed Sep 14
Median ADV $78.0M across their filed names
Open performance→Volume by month
Buys $0
Sells $3.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
AMLXRecent filings
AMLXSALE
Amylyx Pharmaceuticals, Inc.
View filing →
$933K29,025 sh × $32.13
Exec Sep 10
Filed Sep 14 · 4:00 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. View filing → $424K
29,282 sh × $14.47
Exec Mar 2
Filed Mar 4 · 5:30 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. View filing → $228K
15,500 sh × $14.69
Exec Feb 2
Filed Feb 4 · 5:30 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. View filing → $1.8M
136,193 sh × $13.58
Exec Jan 15
Filed Jan 20 · 5:30 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. View filing → $428K
29,775 sh × $14.37
Exec Sep 30 2025
Filed Oct 2 2025 · 5:30 PM ET